Skip to Content
A vastly improved search engine helps you find the latest on companies, business leaders, and news more easily.
The pharma giant had a banner year in 2019, climbing seven slots on the Fortune 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. More recently, Merck has been notably quiet in medical chatter about the novel coronavirus. But executives on a late April earnings call announced that the company has teams scanning its portfolio of antiviral candidates and vaccine assets for potential treatments.
Brendan McDermid—REUTERS
Lists ranking Merck
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...READ MOREview in list
20 Best Workplaces in Biotechnology and Pharmaceuticals - 2021The best U.S. biotechnology and pharmaceutical com...READ MOREview in list
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list
Change the World - 2020As we face unprecedented collective challenges, co...READ MOREview in list
Global 500 - 2020This year's Global 500 generated $33.3 trillion in...READ MOREview in list
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MOREview in list